vorsetuzumab

Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) 是靶向 CD70 抗体的单克隆抗体。Vorsetuzumab 具有抗癌活性，能够加强肾癌细胞巨噬相关吞噬作用，抑制 Burkitt 淋巴瘤。

Vorsetuzumab mafodotin是一种人源化抗CD70单克隆抗体，结合了高效的合成药物负载物monomethyl auristatin F (MMAF)，运用了Seattle Genetics独有的抗体-药物偶联体(ADC)技术。CD70在多种实体肿瘤上有表达，包括肾细胞癌、胰腺癌、卵巢癌、肺癌、多发性骨髓瘤以及多种非霍奇金淋巴瘤。

MMAF Hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF Hydrochloride is an effective tubulin polymerization inhibitor and is used as an antitumor compound.

MMAF sodium is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF sodium is an effective tubulin polymerization inhibitor and is used as an antitumor agent.

MMAFintermediate 1 用于合成MMAF.MMAF (Monomethylauristatin F) 作为一种有效的微管蛋白聚合抑制剂,广泛应用于抗体偶联药物(ADCs)中,充当细胞毒性成分,例如 Vorsetuzumab mafodotin 和 SGN-CD19A 中的 ADC Cytotoxin.

MMAFintermediate 2 用于制备MMAF,后者是一种抗体偶联药物中的细胞毒性成分,具体是微管蛋白聚合抑制剂.MMAF (Monomethylauristatin F) 在多种ADCs中具有应用,例如 Vorsetuzumab mafodotin 和 SGN-CD19A,用于靶向疾病细胞进行治疗.